Canadian Adverse Events Following Immunization Surveillance System (CAEFISS)

The Canadian Adverse Events Following Immunization Surveillance System, or CAEFISS is a federal/provincial/territorial public health post-market vaccine safety monitoring system. CAEFISS has the following objectives:

  1. to continuously monitor the safety of marketed vaccines in Canada;
  2. to identify increases in the frequency or severity of previously identified vaccine-related reactions;
  3. to identify previously unknown adverse events following immunization(AEFI) that could possibly be related to vaccine (unexpected AEFI);
  4. to identify areas that require further investigation and/or research; and
  5. to provide timely information on AEFI reporting profiles for vaccines marketed in Canada that can help inform immunization related decisions.

Public Health Reporting Pathway for Adverse Events Following Immunization (AEFIs) to CAEFISS

The diagram below depicts how AEFI reports flow from origin (vaccine recipient) to the Agency. CAEFISS includes spontaneous, enhanced and active AEFI reporting processes that are further described below. Over 90% of CAEFISS reports are submitted by public health authorities in the provinces and territories, who in turn receive them from local public health units.  Provincial and territorial authorities also receive reports from federal authorities that provide immunization within their jurisdiction (including First Nations and Inuit Health Branch, Correctional Services Canada and Royal Canadian Mounted Police). Most of these reports are generated by nurses, physicians or pharmacists who provide immunizations or who care for individuals with AEFIs. AEFIs received by National Defence and the Canadian Armed Forces are reported directly to the Agency. On rare occasions, AEFI reports are submitted to the Agency directly from physicians, pharmacists, travel clinics and the public.

Market Authorization Holders (MAHs) (i.e. pharmaceutical industry) report serious as well as all unexpected (serious and non-serious) adverse events directly to Health Canada; some MAHs also send reports to the Agency on a voluntary basis. MAH reporting reports less than 5% of all reports received.

Canada also has an active paediatric hospital-based surveillance network for selected serious AEFIs, including but not limited to febrile seizures, other neurologic adverse events, thrombocytopenia, severe vaccination site reactions and intussusception. Known as IMPACT (Immunization Monitoring Program ACTive), the network includes 12 paediatric hospitals across Canada which together represent over 90% of all paediatric tertiary care admissions in the country. At each IMPACT centre, a nurse monitor uses several methods to identify admissions to hospital for the specified adverse events and determines whether or not the events followed immunization and thus should be reported. Each IMPACT centre reports directly to the Agency ensuring timely identification of serious adverse events, and the same report is also sent to public health at the provincial/territorial or local public health unit level depending on standard practice for a given jurisdiction. As each report has a unique IMPACT identification number, it is only entered once into CAEFISS.

Figure 1: Public Health Reporting Pathway for Adverse Events Following Immunization (AEFIs) to CAEFISS

Text Equivalent - Figure 1

Public Health Reporting Pathway for Adverse Events Following Immunization (AEFIs) to CAEFISS

This diagram depicts how the adverse events following immunization reports flow from the origin (vaccine recipient) to the Public Health Agency of Canada. At the top of the diagram is a circle representing the vaccine recipient. From the circle, an arrow points down to a box with the immunization provider and/or health care provider with another arrow pointing from this box down to a box with local public health units. From this box, there is an arrow pointing down to a box with Federal/Provincial/Territorial Immunization Authorities and an arrow pointing to a box with Public Health Agency of Canada (CAEFISS Database). On the left of this flow diagram, is a red box depicting IMPACT with a thick solid arrow pointing from here to the CAEFISS Database box and two dotted arrows pointing from IMPACT to the Federal/Provincial/Territorial Immunization Authorities box and the Local Public Health Units. To the right of the flow diagram is a box titled Market Authorization Holders (MAH) with a dotted line pointing to the CAEFISS Database box.

The flow of AEFI reports as shown in the diagram enable specific actions to be taken at each step along the way.

  • AEFI management, including investigation as appropriate to determine possible cause, is usually undertaken by the reporting immunization or healthcare provider.
  • Individual public health action, such as advice regarding future immunizations, is taken at the Public Health Unit or immunization provider level.
  • Federal/provincial/territorial health authorities collect AEFI reports as part of ongoing evaluation of their immunization programs. At the population level, public health action related to AEFI reports could include changes in immunization program policy.
  • The Agency collates AEFI reports in the Canadian Adverse Event Following Immunization (CAEFI) database for purposes of signal detection analysis and reporting.
  • The Agency shares AEFI data with Health Canada to enable regulatory action related to vaccines marketed in Canada.

CAEFISS data reports and publications

CAEFISS bi-annual reports

CAEFISS quarterly reports

Previously Published Vaccine Safety Reports

AEFI summaries for vaccines administered over specific time periods

Reports on specific vaccines

  • Serious adverse events associated with Bacille Calmette-Guérin vaccine in Canada. Pediatric Infectious Disease Journal 2005; 24:538-541.
  • Influenza vaccine-associated adverse events: Results of passive surveillance, Canada 2001-2002. (archived) CCDR Dec 2002; Vol 28-23:189-196
  • Review of adverse events reported following use of yellow fever vaccine - Canada, 1987-2000. (archived) CCDR Jan 2002; Vol 28-2:9-15.

Reports on specific adverse events

  • Oculo-respiratory syndrome following influenza vaccination: Review of post-marketing surveillance through four influenza seasons in Canada. (archived) CCDR 2005; Vol. 31-21:217-225 Oculo-respiratory syndrome in association with the influenza vaccine: Canada, October-November 2000 (Preliminary report) (archived) CCDR 2000; Vol. 26-23:201.

IMPACT Vaccine Safety Publications (PDF document)

For an electronic copy of these reports, please contact:

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: